

# Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults

Andrea Marengo, MD, Ramy Ibrahim Kamal Jouness, MD,  
Elisabetta Bugianesi, MD, PhD\*



## KEYWORDS

• Steatohepatitis • Hepatocellular carcinoma • Type 2 diabetes • Obesity • Cirrhosis

## KEY POINTS

- Liver-related mortality is the third cause of death in patients with nonalcoholic fatty liver disease (NAFLD) and is significantly higher in patients with nonalcoholic steatohepatitis (NASH) compared with patients with simple steatosis (7.3% vs 0.9% respectively) within the first 15 years of follow-up.
- The presence and severity of fibrosis on liver biopsy is currently the best indicator of long-term liver outcomes in patients with NAFLD.
- The rate of fibrosis progression is at around 1 stage every 6 to 15 years in patients with NASH but is reduced by half in patients with simple steatosis. However, some patients with NAFLD, also with simple steatosis, can progress rapidly to clinically significant fibrosis.
- Patients with NAFLD with cirrhosis have lower rates of liver-related complications but similar overall mortality as compared with patients with hepatitis C virus because of a higher incidence of cardiovascular events.
- Hepatocellular carcinoma incidence is growing in patients with NAFLD with or without cirrhosis, particularly among those with multiple metabolic risk factors.



## INTRODUCTION

The 3 leading causes of death in patients with nonalcoholic fatty liver disease (NAFLD) in descending order are cardiovascular disease, cancer, and liver disease. Although the extrahepatic complications of NAFLD are described elsewhere, this section is focused on the potential liver-related morbidity and mortality that, along with the large prevalence and increasing incidence of this disease in the general population, clearly forecast the future impact of NAFLD on health care.



The authors have nothing to disclose.

Division of Gastroenterology and Hepatology, Department of Medical Sciences, A.O. Città della Salute e della Scienza di Torino, University of Turin, Corso Bramante 88, Turin I-10126, Italy

\* Corresponding author.

E-mail address: [elisabetta.bugianesi@unito.it](mailto:elisabetta.bugianesi@unito.it)



Clin Liver Dis ■ (2015) ■-■

<http://dx.doi.org/10.1016/j.cld.2015.10.010>

[liver.theclinics.com](http://liver.theclinics.com)


1089-3261/15/\$ – see front matter © 2015 Elsevier Inc. All rights reserved.

49 The burden of data on the liver-related complications of NAFLD comes from studies  
50 addressing both the clinical course and the progression of liver damage through  
51 paired liver biopsies, but tackling the natural history of NAFLD is one of the most difficult  
52 challenges for researchers. On one hand, the variety of criteria used to define  
53 NAFLD from the clinical point of view (abnormal liver enzymes, hepatic ultrasound,  
54 indices of liver fat, and liver biopsy), coupled with the lack of sensitivity and specificity  
55 of most of the tests used and the composite nature of NAFLD outcomes, has  
56 hampered most clinical studies. On the other hand, studies based on repeat biopsies  
57 are limited by sampling variability and by the lack of consensus on what is the best  
58 definition of nonalcoholic steatohepatitis (NASH). Several scoring systems have  
59 been described to classify liver histology in adults with NAFLD.<sup>1–3</sup> The NASH Clinical  
60 Research Network (CRN) classification is the most frequently used in recent studies;  
61 however, the NAFLD Activity Score (NAS) has often been used as a surrogate for the  
62 diagnosis of NASH, although it is not designed for it but rather for crude evaluation of  
63 disease severity, once the diagnosis has been established by the overall pathologic  
64 assessment. The prospectively designed Steatosis-Activity-Fibrosis score<sup>2</sup> has  
65 been recently introduced. Despite these caveats, the threat that NAFLD is going to  
66 replace chronic hepatitis C as major cause of liver morbidity and mortality should  
67 be no longer overlooked.

#### 68 69 70 **LIVER DISEASE PROGRESSION IN SIMPLE STEATOSIS AND NONALCOHOLIC 71 STEATOHEPATITIS**

72 Major prospective cohort studies have been derived from Western populations,  
73 whereas data in Asian, African, and Latin American populations are limited  
74 (**Table 1**). The overall long-term mortality of Western patients with the whole spectrum  
75 of NAFLD is 34% to 69% higher than the general population of the same age  
76 and sex within 15 years of follow-up and is mostly due to cardiovascular disease.<sup>4</sup>  
77 In a community-based study of 420 patients from the United States, liver disease  
78 was the third leading cause of death in patients with NAFLD, as compared with the  
79 13 leading causes of death in the general Minnesota population.<sup>5</sup> However, only 21  
80 (5%) patients were diagnosed with cirrhosis, and 3.1% developed liver-related complications,  
81 including one requiring liver transplantation (LT) and 2 developing hepatocellular carcinoma (HCC).  
82 Higher mortality was associated with age (hazard ratio [HR] per decade 2.2; 95% confidence interval [CI] 1.7–2.7),  
83 impaired fasting glucose (HR 2.6; 95% CI 1.3–5.2), and cirrhosis (HR 3.1; 95% CI 1.2–7.8).

84  
85 Importantly, there is a prognostic association between the presence of NASH, the  
86 stage of liver disease (higher fibrosis stage), and the long-term prognosis of patients  
87 with NAFLD. In patients with NASH compared with patients with simple steatosis,  
88 both the prevalence of cirrhosis development (10.8% vs 0.7%, respectively) and  
89 the liver-related mortality are significantly higher (7.3% vs 0.9%) within the first  
90 15 years of follow-up.<sup>10</sup> These findings have been repeatedly confirmed. In a landmark  
91 study,<sup>9</sup> although just 5% of the 129 patients with biopsy-proven NASH enrolled  
92 went on to develop end-stage liver disease, including 3 patients with HCC, liver-related  
93 mortality was increased 10-fold compared with the reference population. However,  
94 in patients with simple steatosis (or steatosis with mild inflammation/cellular injury),  
95 the overall and liver-related mortality risk was not different. In the long-term  
96 follow-up studies available thus far, only 1% of patients with simple steatosis  
97 developed cirrhosis and died a liver-related death after a mean 15.6 years of  
98 follow-up, compared with 11% of those with NASH having or developing cirrhosis,  
99 and 7.3% of those with NASH dying of a liver-related cause after a similar period of



Author (Year)	Diagnosis	Cirrhosis		Follow-up (y)	Main Findings
		Number	Prevalence (%)		
Teli et al, <sup>6</sup> 1995	Bland steatosis	40	0	9.6	There was no progression to NASH/cirrhosis.
Dam-Larsen et al, <sup>7</sup> 2004	Bland steatosis	109	1	16.7	Patients with NAFLD have a benign clinical course without excess mortality.
Matteoni et al, <sup>8</sup> 1999	NAFLD	98	20	8.3	Poor outcomes are more frequent in patients with NASH.
Adams et al, <sup>5</sup> 2005	NAFLD	420	5	7.6	Mortality among patients with NAFLD is higher than the general population.
Ekstedt et al, <sup>9</sup> 2006	NAFLD	129	7.8	13.7	NAFLD with elevated ALT/AST is associated with a significant risk of developing end-stage liver disease. Survival is lower in patients with NASH.
Söderberg et al, <sup>10</sup> 2010	NAFLD	143	9	28.0	Patients with NASH are at increased risk of death compared with the general population.
Lee, <sup>11</sup> 1989	NASH	39	16.3	3.8	NASH has the potential to progress into cirrhosis.
Powell et al, <sup>12</sup> 1990	NASH	42	7	4.5	NASH should be recognized as a further cause of CC.
Evans et al, <sup>13</sup> 2002	NASH	26	4	8.7	There is no evidence of progressive chronic liver injury in patients with NASH.
Hashimoto et al, <sup>14</sup> 2005	NASH septal fibrosis/cirrhosis	89	48	3.7	The most important consequence of patients with NAFLD with advanced fibrosis was HCC.
Sanyal et al, <sup>15</sup> 2006	Cirrhotic-stage NASH	152	100	10.0	NASH-cirrhosis has a lower mortality rate compared with HCV-cirrhosis but a greater CV mortality.
Ascha et al, <sup>16</sup> 2010	Cirrhotic-stage NASH	195	100	3.2	Patients with NASH-cirrhosis have an increased risk of HCC.
Bhala et al, <sup>17</sup> 2011	NASH septal fibrosis/cirrhosis	247	54	7.4	Patients with NAFLD-cirrhosis have lower rates of liver-related complications and HCC than patients with HCV infection but similar overall mortality.
Stepanova et al, <sup>18</sup> 2013	NASH	289	NA	12.5	Patients with NASH have a higher risk of liver-related mortality than non-NASH.

Abbreviations: ALT/AST, alanine/aspartate aminotransferase; CC, cryptogenic cirrhosis; CV, cardiovascular; HCC, hepatocellular carcinoma; NA, not available.

151 follow-up,<sup>4</sup> leading to the concept that simple steatosis is a relatively “benign state,”  
 152 whereas NASH represents the form of NAFLD potentially progressive to cirrhosis and  
 153 its complications (Fig. 1).

154 However, it is important to discriminate which of the histologic features of NASH  
 155 are true determinants of long-term prognosis. In a cohort of 256 Swedish subjects,  
 156 after a follow-up of up to 28 years, 40% of the 118 subjects with a histologic diagnosis  
 157 of NAFLD died.<sup>10</sup> Compared with the total Swedish population, adjusted for sex, age,  
 158 and calendar period, subjects with bland steatosis exhibited a 55% increased mortality  
 159 and subjects with NASH 86%. Quite surprisingly, the study reported similar  
 160 overall-related and liver-related mortality between the groups with and without definitive  
 161 NASH (classified with the NASH CRN scoring system). However, 67% of patients  
 162 classified as non-NASH in this study had liver fibrosis or even well-established  
 163 cirrhosis, as fibrosis is not included in the NAS score. Thus, most likely the difference  
 164 between the prognosis of NASH and simple steatosis is due to the greater likelihood  
 165 of fibrosis being present in patients with NASH. This concept is supported by several  
 166 studies. A more recent survey<sup>19</sup> conducted on 209 patients with NAFLD with a median  
 167 12 years of follow-up showed the presence of NASH correlated with liver mortality  
 168 only when fibrosis was included in its definition, and the risk was highest with  
 169 bridging fibrosis and cirrhosis (HR 5.68, 95% CI 1.5–21.5). Thus, it would seem likely  
 170 that the presence and severity of fibrosis at liver biopsy would be the most important  
 171 histologic determinant of long-term prognosis. Further evidence comes from recent  
 172 studies demonstrating that noninvasive scoring systems correlating with the degree  
 173 of fibrosis are capable of predicting liver-related events, LT, and death in patients with  
 174 NAFLD.<sup>20</sup>

175 The rate of fibrosis progression in NAFLD is generally slow, and regression may also  
 176 occur; but a subset of patients either with NASH or simple steatosis can develop  
 177 severe liver damage quite rapidly (see Fig. 1). In a systematic review and meta-analysis<sup>21</sup>  
 178 including 411 patients with biopsy-proven NAFLD (63% with NASH), over  
 179 2145.5 person-years of follow-up, 33.6% had fibrosis progression, 43.1% had stable  
 180 fibrosis, and 22.3% had an improvement in fibrosis stage. The annual fibrosis progression  
 181 rate in patients with NASH was doubled compared with that in patients with  
 182




Fig. 1. Risk stratification for fibrosis progression in NAFLD.

202 simple steatosis; overall, one stage of fibrosis progression in patients with NASH  
203 occurred over 7.1 years in NASH versus 14.3 years in those with simple steatosis.  
204 However, the proportion of fibrosis progressors who moved from stage 0 to advanced  
205 (stage 3 or 4) fibrosis (rapid progressors) was identical in the 2 histologic subgroups  
206 (17% of patients with steatosis and 18% of patients with NASH). Similarly, a recent  
207 study has challenged the current concept that simple steatosis is a benign disease  
208 and cannot progress to significant liver damage. In a cohort of 108 patients from  
209 the United Kingdom with serial biopsies,<sup>22</sup> 81 had a baseline histologic diagnosis of  
210 NASH (75%) and 27 (25%) of NAFLD. The mean annual rate of fibrosis progression  
211 was  $0.08 \pm 0.25$  stages. Remarkably, 44% of patients with baseline NAFLD developed  
212 NASH, including 10 patients in which fibrosis worsened over time (3 of 10 progressed  
213 by 1 stage, 5 by 2 stages, and 2 by 3 stages). No difference in the proportion exhibiting  
214 fibrosis progression was found between patients with steatosis or NASH at index bi-  
215 opsy (37% vs 43%), although all patients with steatosis developing fibrosis had also  
216 developed NASH on follow-up biopsy (see Fig. 1). Of note, 44% of the patients with  
217 steatosis developed NASH after a median 8 years of follow-up, suggesting that  
218 NASH usually develops after steatosis. Overall, these data suggest that the necroin-  
219 flammatory damage per se is not as important as fibrosis for the long-term prognosis  
220 of patients with NAFLD and accordingly the major focus of therapy should be in the  
221 resolution of fibrosis rather than of the other histologic features of NASH.



#### 222 223 **RISK FACTORS FOR DISEASE PROGRESSION IN SIMPLE STEATOSIS AND** 224 **NONALCOHOLIC STEATOHEPATITIS** 225

226 Provided that the presence and severity of fibrosis is the key factor determining long-  
227 term, liver-related mortality, the key question is which are the main determinants of  
228 NAFLD progression that can be identified without a liver biopsy. Age, body mass in-  
229 dex (BMI), type 2 diabetes mellitus (T2DM) or metabolic syndrome (MetS), and insulin  
230 resistance assessed by homeostasis model assessment are well-recognized risk factors  
231 for advanced fibrosis in multiple cross-sectional studies; but few of them have  
232 also been examined in longitudinal studies and in relation to their ability to predict  
233 the progression of NAFLD. In the previously cited meta-analysis,<sup>21</sup> the presence of  
234 hypertension (odds ratio [OR] 1.94; 95% CI 1.00–3.74) and a low aspartate amino-  
235 transferase (AST)/alanine transaminase (ALT) ratio at the time of baseline biopsy  
236 was associated with the progression of fibrosis, whereas in the most recent study,<sup>22</sup>  
237 most (80%) of the patients with NAFLD in which fibrosis worsened were diabetic and  
238 had a longer disease duration. Fibrosis progressors had also a significantly lower  
239 platelet count ( $P = .04$ ) and higher AST/ALT ratio ( $P = .04$ ) and Fibrosis 4 (FIB-4)  
240 score ( $P = .02$ ) than nonprogressors. The same study identified the FIB-4 score as  
241 the only significant baseline factor able to predict fibrosis progression, whereas the  
242 presence of T2DM (OR 6.25; CI 1.88–20) and FIB-4 score (OR 3.1; CI 1.4–6.8,  
243  $P = .004$ ) at the time of follow-up liver biopsy were indicators of the presence of  
244 fibrosis.

245 Among genetic factors, homozygosity for the patatin-like phospholipase domain-  
246 containing protein (PNPLA3) 148M allele has been associated with a 3.3-fold  
247 increased risk of both NASH and liver fibrosis independent of BMI, T2DM, and stea-  
248 tosis (for NASH) and age, BMI, T2DM, steatosis, and NASH (for fibrosis).<sup>23</sup> The as-  
249 sociation between PNPLA3 I148M and the severity of fibrosis in NAFLD has been  
250 almost contemporarily replicated by independent groups in adults<sup>24,25</sup> and in the  
251 pediatric population<sup>26</sup> and confirmed by a recent meta-analysis.<sup>27</sup> Studies on the  
252 ability of genetic and other factors to predict the risk of disease progression are

253 definitely needed, not only in the Western population but also in other developed  
254 and developing countries where the risk of NAFLD is paralleling the economic  
255 development.  
256

### 257 LIVER DISEASE PROGRESSION IN NONALCOHOLIC STEATOHEPATITIS-RELATED 258 CIRRHOSIS

259 It is well established that patients with severe liver damage are more likely to develop  
260 liver-related complications, and pooled data from long-term (~10 years) follow-up  
261 studies of patients with NAFLD with advanced fibrosis and cirrhosis demonstrate a  
262 16% mortality with 60% of the deaths liver-related compared with only approximately  
263 9% liver-related in long-term (~15 years) follow-up studies of patients with NAFLD  
264 without advanced fibrosis or cirrhosis.<sup>4</sup> However, the natural history of cirrhosis due  
265 to NASH has been addressed by only few studies.

266 In an Australian study of 23 patients with NASH cirrhosis identified from a hospital  
267 database, the 10-year survival rate was 84%. Comparing these patients to subjects  
268 affected by hepatitis C virus (HCV)-related cirrhosis, the study showed no difference  
269 between liver-related deaths or all-cause mortality between the two groups after  
270 adjustment for baseline differences, despite a trend toward improved survival in  
271 NASH.<sup>28</sup> In a larger study,<sup>15</sup> the 10-year survival in the NASH group was 80.9%,  
272 significantly better than in the HCV controls of similar age, sex, and Child-Pugh score,  
273 principally because of a lower risk of hepatic decompensation in the NASH cohort. In  
274 subjects with NASH-related cirrhosis, ascites was the first and most common clinical  
275 feature of decompensation but occurred at a slower rate than in patients with HCV.  
276 Once ascites developed, the rate of hepatorenal syndrome was similar in the two  
277 groups. Development of varices and the rates of variceal hemorrhage were similar  
278 in NASH-related and HCV-related cirrhosis, whereas the incidence of hepatic en-  
279 cephalopathy was intermediate between that for ascites and variceal hemorrhage.  
280 Remarkably, subjects with NASH-related cirrhosis had a significantly higher rate of  
281 cardiovascular mortality compared with HCV-related cirrhosis. These data have  
282 been corroborated in another independent cohort.<sup>16</sup> In a multicenter prospective  
283 study,<sup>17</sup> the long-term morbidity and mortality of 247 patients with NAFLD advanced  
284 fibrosis or cirrhosis was compared with 264 patients with HCV cirrhosis. Both cohorts  
285 were Child-Pugh class A and had cirrhosis confirmed by liver biopsy. In the NAFLD  
286 cohort, liver-related complications occurred in 19.4% of cases and deaths or LT in  
287 13.4%, compared with 16.7% and 9.4%, respectively, in the HCV cohort. When  
288 adjusting for baseline differences in age and sex, the cumulative incidence of liver-  
289 related complications was lower in the NAFLD than the HCV cohort, including inci-  
290 dent HCC; but cardiovascular events and overall mortality were similar in both  
291 groups. Thus, NAFLD seems to have lower rates of liver-related complications but  
292 a similar overall mortality compared with patients with HCV. Fibrosis stage and stan-  
293 dard clinical and biochemical parameters are relevant in assessing the risk of future  
294 liver complications.  
295

### 296 HEPATOCELLULAR CARCINOMA IN NONALCOHOLIC FATTY LIVER DISEASE 297

298 The exact burden of HCC related to NAFLD remains uncertain, but it is clear that  
299 NAFLD is going to be the most common underlying etiologic risk factor for HCC. In  
300 a population-based study in the United States, NAFLD accounted for 59% of HCC  
301 cases, with a cumulative incidence of 0.3% over a 6-year follow-up.<sup>29</sup> The mortality  
302 rates for HCC ranged from 0.25% to 2.3% over 8.3 and 13.7 years of follow-up in 2  
303 further studies.<sup>8,9</sup> In the largest prospective community-based study performed so



304 far,<sup>30</sup> after a mean follow-up of 7.6 years, only 0.5% patients developed HCC; but the  
305 rate among cirrhotic patients was 10%. As expected, the risk of HCC is more elevated  
306 when examining patients with advanced liver disease; but patients with NAFLD with  
307 HCC have a lower prevalence of cirrhosis than patients with HCC in HCV-related  
308 and other liver diseases. This prevalence is an important characteristic of HCC in  
309 NAFLD, which has been reported in multiple publications (Table 2).



### ***Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis-Related Cirrhosis***

312 Two longitudinal studies on the natural history of NASH-related cirrhosis in the United  
313 States<sup>15</sup> and Japan<sup>30</sup> confirmed that HCC was the cause of 47% of deaths in patients  
314 with NASH, representing an independent risk factor for liver-related mortality (HR  
315 7.96). Overall, the relative HCC risk and mortality rate in NASH-related cirrhosis seems  
316 to be lower in comparison with viral or alcohol-related cirrhosis. In a large cohort  
317 study, HCC was significantly more common in HCV than NAFLD (6.8% vs 2.4%,  
318 respectively)<sup>17</sup> and the HCV cohort had an approximate 0.15% risk per year of HCC  
319 development versus 0.05% in NAFLD. However, the perception that HCC is a rare  
320 and late complication of NAFLD has been denied by recent reports. In North East  
321 England, the overall incidence of HCC increased 1.8-fold from 2000 to 2010; but  
322 most shocking was a more than 10-fold increase in HCC associated with NAFLD, ac-  
323 counting for 34.8% of all the cases in 2010 and making it the single most common un-  
324 derlying cause.<sup>39</sup> Not surprisingly, this increasing incidence of HCC was associated  
325 with an increasing prevalence of overweight and obesity (61.0% in 2000 and 65.5%  
326 in 2010). This finding confirms that the apparently lower rates of HCC arising in  
327 NAFLD-cirrhosis compared with other causes of chronic liver disease are definitely  
328 outweighed by the much larger spread of NAFLD in the general population and  
329 open future scenarios in the approach to HCC.

### ***Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease Without Cirrhosis***

333 The most worrisome issue consistently emerging in the last years is the onset of  
334 HCC in patients with NAFLD who do not have cirrhosis yet. A French study analyzed  
335 a cohort of 31 patients with HCC with MetS as the only risk factor for liver disease  
336 and found mild or no fibrosis in most cases, compared with those harboring HCC  
337 associated with an overt cause of liver disease (65% vs 26%,  $P < .0001$ ).<sup>38</sup>  
338 The absence of cirrhosis was further confirmed in 38% of Japanese patients<sup>41</sup>  
339 and in one-third of patients from North East England with NAFLD-related HCC.<sup>41</sup>  
340 As patients without cirrhosis are not in surveillance programs, most (62.3%) pre-  
341 sented symptomatically with larger tumors, and their median survival was just  
342 7.2 months.<sup>39</sup>

343 In conclusion, HCC in NAFLD should not be underestimated for several reasons.  
344 First, once cirrhosis had developed, HCC represents a frequent complication, with  
345 an incidence of up to 10% over a 7-year follow-up. Secondly, HCC can also arise in  
346 the absence of cirrhosis in patients with NASH with multiple metabolic risk factors,  
347 mainly obesity and T2DM. These observations arouse an urgent need to better under-  
348 stand the risk factors linked to the development of HCC, especially in noncirrhotic  
349 livers, and to update screening programs.

### ***Nonalcoholic Fatty Liver Disease in Lean Patients***

352 A small but significant proportion of patients (7%–21%) develops NAFLD despite  
353 normal BMI, and they are defined as lean or normal weight NAFLD.<sup>42–46</sup> They are  
354 generally described in the Asian populations; but within the National Health and

355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405**Table 2**  
**Principal studies on the association between NAFLD and HCC**

Author (Year)	Diagnosis	Study Population	Main Findings
Bugianesi et al, <sup>31</sup> 2002	Cirrhosis	641 patients with cirrhosis-associated HCC	NAFLD-related features are more frequent in HCC arising in CC than viral or alcoholic cirrhosis.
Marrero et al, <sup>32</sup> 2002	Cirrhosis	105 patients with HCC	CC-related HCC was less likely to have undergone HCC surveillance and had larger tumors at diagnosis.
Regimbeau et al, <sup>33</sup> 2004	Cirrhosis	210 patients who underwent resection for HCC	Obesity and T2DM may be important risk factors for HCC, via NAFLD and CC.
Ascha et al, <sup>16</sup> 2010	Cirrhosis	510 patients with cirrhosis	Patients with NASH cirrhosis have an increased risk of HCC yearly cumulative incidence (2.6% vs 4.0% in HCV).
Yasui et al, <sup>34</sup> 2011	Cirrhosis and NAFLD/NASH	87 HCC cases; no cirrhosis in 43 patients	Most patients with NASH who develop HCC are men with features of MetS and at a less advanced stage of liver fibrosis.
Mittal et al, <sup>35</sup> 2015	Cirrhosis	1500 patients with HCC	NAFLD is the third most common risk factor for HCC. Cirrhosis was less common in NAFLD-related cases compared with alcoholic or HCV-related HCC.
Wong et al, <sup>36</sup> 2014	Cirrhosis	10,061 adult LT recipients for HCC	NAFLD is the most rapidly growing indication for LT in HCC cases in the United States.
Tateishi et al, <sup>37</sup> 2015	Cirrhosis	33,782 patients with HCC (596 NAFLD related)	Most cases of nonviral HCC are related to lifestyle factors, including obesity and T2DM.
Paradis et al, <sup>38</sup> 2009	NAFLD/NASH	31 patients with HCC with MetS as the only risk factor for liver disease	NAFLD contributes to noncirrhotic HCC.
Dyson et al, <sup>39</sup> 2014	Cirrhosis and NAFLD/NASH	623 patients with HCC	HCC cases without cirrhosis most commonly occurred in NAFLD. Patients without cirrhosis were not in surveillance programs, and most presented symptomatically with larger tumors.
Leung et al, <sup>40</sup> 2015	Cirrhosis and NAFLD/NASH	54 patients with NAFLD-associated HCC	HCC can develop in NAFLD without cirrhosis. At diagnosis, such tumors are larger than those in cirrhotic patients.

Abbreviation: CC, cryptogenic cirrhosis.



406 Nutrition Examination Survey III cohort, 7.4% of subjects had a normal BMI (<25 kg/  
407 m<sup>2</sup>).<sup>47</sup> Lean individuals with NAFLD constitute a subgroup of patients relatively free  
408 from MetS, although insulin resistance can be increased anyway compared with  
409 healthy controls.<sup>48</sup> The common variant in the PNPLA3 gene (I148M) can partially  
410 explain the onset of NAFLD in lean patients; but in a recent study,<sup>46</sup> PNPLA3 polymor-  
411 phism did not contribute to incident NAFLD.

412 The pivotal question is whether lean patients with NAFLD have a different disease  
413 progression compared with obese patients with NAFLD, but the answer is still  
414 unknown because of the paucity of clinical and histologic outcome data. In a  
415 biopsy series, leaner Asian patients with NASH were less likely to have advanced  
416 fibrosis and cirrhosis than Caucasians.<sup>49</sup> However, the preliminary report of an in-  
417 ternational study indicated a more severe prognosis in lean subjects with biopsy-  
418 proven NAFLD compared with overweight/obese subjects.<sup>50</sup> In a cohort of 1090  
419 NAFLD cases, only 125 (11.5%) were classified as lean at first diagnosis. In accordance with previous studies, lean patients with NAFLD were characterized by a lower prevalence of T2DM, hypertension, hypertriglyceridemia, low high-density lipoproteins cholesterol, central obesity, and MetS as well as more frequently normal liver enzymes and a lower prevalence or severity of insulin resistance. Histology was characterized by milder degrees of steatosis and fibrosis but more severe lobular inflammation. In a subgroup of 483 patients, whereby the index liver biopsy had been performed before 2005, the difference in overall mortality between the lean and nonlean NAFLD group was analyzed. Over a follow-up of 11 years, 71 of the 483 (14.7%) patients died; surprisingly, the cumulative survival was significantly shorter in lean patients with NAFLD as compared with non-lean NAFLD (log-rank test = 5.6;  $P < .02$ ). This difference remained significant when adjusted in a Cox regression model, with only lean NAFLD (HR 11.8; 95% CI 2.8–50.1;  $P = .001$ ) and age (HR 1.05; 95% CI 1.008–1.1;  $P = .02$ ) identified as prognostic factors. These provocative data point out that the definition of risk factors for the progression of NAFLD is still an open issue and that we should not quickly discharge lean patients with NAFLD from the gastroenterology outpatients clinic, overlooking their potential liver-related complications.



## 437 438 SUMMARY

439  
440 Patients with NAFLD are at risk of liver-related complications and death; but fibrosis  
441 progression is generally slow, taking around 8 years to progress from stage 0 to  
442 stage 1 fibrosis, although there is a subgroup of rapid progressors who can prog-  
443 ress 3 to 4 stages within 2 to 6 years. There is a prognostic association between  
444 the histologic stage of liver disease and the long-term prognosis of patients with  
445 NAFLD. Currently the presence and severity of fibrosis at index biopsy is the best  
446 indicator of the long-term liver outcome. Pooled data from long-term follow-up  
447 studies of NAFLD demonstrate only approximately 9% of liver-related deaths in pa-  
448 tients without advanced fibrosis or cirrhosis, whereas patients with NAFLD with  
449 advanced fibrosis and cirrhosis demonstrate a 16% mortality with 60% of the  
450 deaths liver related. Among nonhistologic predictors, hypertension and T2DM at  
451 presentation are the factors most consistently associated with the risk of disease  
452 progression that is observed also in lean patients. HCC is a worrisome growing  
453 complication of NAFLD at any stage. Scientific advances in the understanding of  
454 mechanisms of fibrosis and carcinogenesis in NAFLD are awaited with interest in  
455 order to provide clinical indexes to predict and prevent the risk of liver-related  
456 deaths.

## REFERENCES

1. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. *Hepatology* 2005;41:1313–21.
2. Bedossa P, Flip Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. *Hepatology* 2014;60:565–75.
3. Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. *Hepatology* 2011;53:810–20.
4. Angulo P. The natural history of NAFLD. In: Farrell GC, McCullough AJ, Day CP, editors. *Non-alcoholic fatty liver disease: a practical guide*. London: Wiley Blackwell Press; 2013. p. 37–45.
5. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 2005;129:113–21.
6. Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. *Hepatology* 1995;22:1714–9.
7. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. *Gut* 2004;53:750–5.
8. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999;116:1413–9.
9. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006;44:865–73.
10. Söderberg C, Ståhl P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. *Hepatology* 2010;51:595–602.
11. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. *Hum Pathol* 1989;20:594–8.
12. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. *Hepatology* 1990;11:74–80.
13. Evans CD, Oien KA, MacSween RN, et al. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? *J Clin Pathol* 2002;55:689–92.
14. Hashimoto E, Yatsuji S, Kaneda H, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. *Hepatol Res* 2005;33:72–6.
15. Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. *Hepatology* 2006;43:682–9.
16. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Hepatology* 2010;51:1972–8.
17. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. *Hepatology* 2011;54:1208–16.
18. Stepanova M, Rafiq N, Makhlof H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). *Dig Dis Sci* 2013;58:3017–23.
19. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. *Hepatology* 2011;53:1874–82.

- 508 20. Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict  
509 long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterol-*  
510 *ogy* 2013;145:782–9.
- 511 21. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver  
512 vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-  
513 biopsy studies. *Clin Gastroenterol Hepatol* 2015;13:643–54.
- 514 22. McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from  
515 steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prog-  
516 nosis and clinical management. *J Hepatol* 2015;62:1148–55.
- 517 23. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholi-  
518 pase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with  
519 nonalcoholic fatty liver disease. *Hepatology* 2010;51:1209–17.
- 520 24. Rotman Y, Koh C, Zmuda JM, et al. The association of genetic variability in patatin-  
521 like phospholipase domain-containing protein 3 (PNPLA3) with histological  
522 severity of nonalcoholic fatty liver disease. *Hepatology* 2010;52:894–903.
- 523 25. Speliotes EK, Butler JL, Palmer CD, et al. PNPLA3 variants specifically confer  
524 increased risk for histologic nonalcoholic fatty liver disease but not metabolic dis-  
525 ease. *Hepatology* 2010;52:904–12.
- 526 26. Valenti L, Alisi A, Galmozzi E, et al. I148M patatinlike phospholipase domain-  
527 containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.  
528 *Hepatology* 2010;52:1274–80.
- 529 27. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like  
530 phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histo-  
531 logical severity of nonalcoholic fatty liver disease. *Hepatology* 2011;53:1883–94.
- 532 28. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalco-  
533 holic steatohepatitis compared with hepatitis C. *Hepatology* 2003;38:420–7.
- 534 29. Sanyal A, Poklepovic A, Moyneur E, et al. Population-based risk factors and  
535 resource utilization for HCC: US perspective. *Curr Med Res Opin* 2010;26:2183–91.
- 536 30. Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis  
537 due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic  
538 hepatitis C. *J Gastroenterol Hepatol* 2009;24:248–54.
- 539 31. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalco-  
540 holic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.  
541 *Gastroenterology* 2002;123:134–40.
- 542 32. Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver  
543 disease in patients with hepatocellular carcinoma in the United States. *Hepatol-*  
544 *ogy* 2002;36:1349–54.
- 545 33. Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk  
546 factor for hepatocellular carcinoma. *Liver Transpl* 2004;10:S69–73.
- 547 34. Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonal-  
548 coholic steatohepatitis who develop hepatocellular carcinoma. *Clin Gastroenterol*  
549 *Hepatol* 2011;9:428–33.
- 550 35. Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver  
551 disease-related hepatocellular carcinoma in the veteran affairs population. *Clin*  
552 *Gastroenterol Hepatol* 2015;13:594–601.
- 553 36. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly  
554 growing indication for liver transplantation in patient with hepatocellular carcinoma  
555 in the U.S. *Hepatology* 2014;59:2188–95.
- 556 37. Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and  
557 prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multi-  
558 center cohort study. *J Gastroenterol* 2015;50:350–60.



- 559 38. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with  
560 metabolic syndrome often develop without significant liver fibrosis: a pathological  
561 analysis. *Hepatology* 2009;49:851–9.
- 562 39. Dyson J, Jaques B, Chattopadhyay D, et al. Hepatocellular cancer: the impact of  
563 obesity, type 2 diabetes and multidisciplinary team. *J Hepatol* 2014;60:110–7.
- 564 40. Leung C, Yeoh SW, Patrick D, et al. Characteristics of hepatocellular carcinoma in  
565 cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. *World J Gastroenterol*  
566 2015;21:1189–96.
- 567 41. Tokushige K, Hashimoto E, Horie Y, et al. Hepatocellular carcinoma in Japanese  
568 patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic  
569 liver disease of unknown etiology: report of the nationwide survey. *J Gastroenterol*  
570 2011;46:1230–7.
- 571 42. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease  
572 and advanced fibrosis in Hong Kong Chinese: a population study using proton-  
573 magnetic resonance spectroscopy and transient elastography. *Gut* 2012;61:  
574 409–15.
- 575 43. Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country  
576 has a high prevalence of nonalcoholic fatty liver and significant liver disease.  
577 *Hepatology* 2010;51:1593–602.
- 578 44. Kwon YM, Oh SW, Hwang SS, et al. Association of nonalcoholic fatty liver disease  
579 with components of metabolic syndrome according to body mass index in  
580 Korean adults. *Am J Gastroenterol* 2012;107:1852–8.
- 581 45. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian  
582 people who are not obese. *J Gastroenterol Hepatol* 2012;27:1555–60.
- 583 46. Wong VW, Wong GL, Yeung DK, et al. Incidence of non-alcoholic fatty liver disease  
584 in Hong Kong: a population study with paired proton-magnetic resonance spec-  
585 troscopy. *J Hepatol* 2015;62:182–9.
- 586 47. Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean  
587 individuals in the United States. *Medicine* 2012;91:319–27.
- 588 48. Vos B, Moreno C, Nagy N, et al. Lean nonalcoholic fatty liver disease (Lean-NAFLD):  
589 a major cause of cryptogenic liver disease. *Acta Gastroenterol Belg* 2011;74:  
590 389–94.
- 591 49. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using  
592 liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology*  
593 2010;51:454–62.
- 594 50. Dela Cruz AC, Bugianesi E, George J, et al. Characteristics and long-term prognosis  
595 of lean patients with non-alcoholic fatty liver disease. *Gastroenterology* 2014;146:  
596 S-909.

**AUTHOR QUERY FORM**

 <b>ELSEVIER</b>	<b>Journal:</b> CLD  <b>Article Number:</b> 798	
--	---	--

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof.

<b>Location in article</b>	<b>Query / Remark: Click on the Q link to find the query's location in text Please insert your reply or correction at the corresponding line in the proof</b>
<b>Q1</b>	Please approve the short title to be used in the running head at the top of each right-hand page.
<b>Q2</b>	Are author names and order of authors OK as set?
<b>Q3</b>	<p>This is how your name will appear on the contributor's list. <b>Please add your academic title</b> and any other necessary titles and professional affiliations, verify the information, and OK</p> <p><b>ANDREA MARENGO, MD</b>, Division of Gastroenterology and Hepatology, Department of Medical Sciences, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy</p> <p><b>RAMY IBRAHIM KAMAL JOUNESS, MD</b>, Division of Gastroenterology and Hepatology, Department of Medical Sciences, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy</p> <p><b>ELISABETTA BUGIANESI, MD, PhD</b>, Division of Gastroenterology and Hepatology, Department of Medical Sciences, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy</p>
<b>Q4</b>	<p>The following synopsis is the one that you supplied but edited down to less than 100 words. Please confirm OK or submit a replacement (also less than 100 words). Please note that the synopsis will appear in PubMed: Liver-related mortality is the third cause of death in patients with nonalcoholic fatty liver disease, but the long-term prognosis basically depends on the presence and severity of liver damage. Thus, life expectancy in patients with simple steatosis is not different from the general population, but liver-related mortality is significantly higher in patients with nonalcoholic steatohepatitis (NASH), particularly in those with advanced fibrosis. Progression of liver disease is observed in up to one-third of patients with NASH. The long-term hepatic prognosis mostly depends on the histologic stage at initial liver biopsy, but multiple risk factors may concur.</p>
<b>Q5</b>	Please verify the affiliation address.
<b>Q6</b>	As per the editorial remarks, "Per Clinics style only 3–5 key points are allowed. Hence the sixth key point list has been deleted." Please verify.
<b>Q7</b>	Please check the article throughout to be sure the edits preserve your intent.

(continued on next page)

- Q8** If there are any drug dosages in your article, please verify them and indicate that you have done so by initialing this query.
- Q9** Please verify that the hierarchy of the heading levels are OK as set.
- Q10** Please clarify whether the quote “benign state” is a direct quote and provide the corresponding reference citation if it is.
- Q11** Please verify the term “progressors.”
- Q12** Please verify the term “necroinflammatory.”
- Q13** Please verify that the addition of the term “prevalence” preserves your intent in the sentence beginning “This prevalence is an...”
- Q14** Please note that, per Clinics style, the term *case* refers to the instance of a disease and not a person. Please verify that the use of the term *case* in the article reflects Clinics style.
- Q15** Please verify the third editor name in Ref. 4.
- Q16** Symbol "\*" that was cited in certain references has been removed. Please verify.
- Q17** Reference citations were not in sequential order. Hence, Refs. 6–22, 31–41 have been renumbered both in text and in reference list. Please verify.
- Q18** ALT is expanded in the original manuscript’s abbreviation list as “alanine transaminase” but as “alanine aminotransferase” in the Table 1 abbreviation list. Please clarify which expansion is correct.

Please check this box or indicate  
your approval if you have no  
corrections to make to the PDF file

Thank you for your assistance.